<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00933231</url>
  </required_header>
  <id_info>
    <org_study_id>FKC-014</org_study_id>
    <nct_id>NCT00933231</nct_id>
  </id_info>
  <brief_title>Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts</brief_title>
  <official_title>A Comparison of Effects of Standard Dose vs. Low Dose Advagraf® With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Canada, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre study examining the use of Advagraf-minimization strategy and/or the
      use of an inhibitor of the renin-angiotensin system in reducing chronic rejection in renal
      allografts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of the following 4 treatment groups.:

        1. Standard dose Advagraf with angiotensin-converting enzyme inhibitor (ACEi)/angiotensin
           receptor blocker (ARB) antihypertensive therapy

        2. Standard dose Advagraf without ACEi/ARB antihypertensive therapy

        3. Low dose Advagraf with ACEi/ARB antihypertensive therapy

        4. Low dose Advagraf without ACEi/ARB antihypertensive therapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 17, 2009</start_date>
  <completion_date type="Actual">April 3, 2018</completion_date>
  <primary_completion_date type="Actual">May 11, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of allograft interstitial fibrosis and tubular atrophy (IF/TA) as assessed at a central pathology lab</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of allograft IF/TA between 6 and 24 months as assessed at a central pathology lab</measure>
    <time_frame>6 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function will be evaluated by estimation of glomerular filtration rate (GFR), serum creatinine, and urine protein:creatinine ratio</measure>
    <time_frame>1, 3, 6, 12 months and annually thereafter (Up to 5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure and the use of antihypertensive agents will be evaluated</measure>
    <time_frame>1, 3, 6, 12 months and annually thereafter</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">281</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Standard dose Advagraf with ACEi/ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dose Advagraf will be evaluated with ACEi/ARB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose Advagraf without ACEi/ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dose Advagraf will be evaluated without ACEi/ARB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose Advagraf with ACEi/ARB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Advagraf will be evaluated with ACEi/ARB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose Advagraf without ACEi/ARB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose Advagraf will be evaluated without ACEi/ARB</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Standard dose, Oral</description>
    <arm_group_label>Standard dose Advagraf without ACEi/ARB</arm_group_label>
    <arm_group_label>Standard dose Advagraf with ACEi/ARB</arm_group_label>
    <other_name>Advagraf</other_name>
    <other_name>FK506XL</other_name>
    <other_name>Prolonged Release Tacrolimus</other_name>
    <other_name>Tacrolimus XL</other_name>
    <other_name>Extended Release Tacrolimus</other_name>
    <other_name>FK506E</other_name>
    <other_name>MR4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>Low dose, Oral</description>
    <arm_group_label>Low-dose Advagraf with ACEi/ARB</arm_group_label>
    <arm_group_label>Low-dose Advagraf without ACEi/ARB</arm_group_label>
    <other_name>Prolonged Release Tacrolimus</other_name>
    <other_name>FK506XL</other_name>
    <other_name>Extended Release Tacrolimus</other_name>
    <other_name>Tacrolimus XL</other_name>
    <other_name>FK506E</other_name>
    <other_name>MR4</other_name>
    <other_name>Advagraf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Simulect</intervention_name>
    <description>IV</description>
    <arm_group_label>Standard dose Advagraf without ACEi/ARB</arm_group_label>
    <arm_group_label>Low-dose Advagraf with ACEi/ARB</arm_group_label>
    <arm_group_label>Low-dose Advagraf without ACEi/ARB</arm_group_label>
    <arm_group_label>Standard dose Advagraf with ACEi/ARB</arm_group_label>
    <other_name>Basiliximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cellcept</intervention_name>
    <description>Oral</description>
    <arm_group_label>Standard dose Advagraf without ACEi/ARB</arm_group_label>
    <arm_group_label>Low-dose Advagraf with ACEi/ARB</arm_group_label>
    <arm_group_label>Low-dose Advagraf without ACEi/ARB</arm_group_label>
    <arm_group_label>Standard dose Advagraf with ACEi/ARB</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticosteroids</intervention_name>
    <description>IV and Oral</description>
    <arm_group_label>Standard dose Advagraf without ACEi/ARB</arm_group_label>
    <arm_group_label>Low-dose Advagraf with ACEi/ARB</arm_group_label>
    <arm_group_label>Low-dose Advagraf without ACEi/ARB</arm_group_label>
    <arm_group_label>Standard dose Advagraf with ACEi/ARB</arm_group_label>
    <other_name>Methylprednisolone</other_name>
    <other_name>prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Oral</description>
    <arm_group_label>Low-dose Advagraf with ACEi/ARB</arm_group_label>
    <arm_group_label>Standard dose Advagraf with ACEi/ARB</arm_group_label>
    <other_name>Altace</other_name>
    <other_name>ACEi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Oral</description>
    <arm_group_label>Low-dose Advagraf with ACEi/ARB</arm_group_label>
    <arm_group_label>Standard dose Advagraf with ACEi/ARB</arm_group_label>
    <other_name>Avapro</other_name>
    <other_name>ARB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is the recipient of a first or second deceased or living donor renal
             transplant (one kidney only)

          -  Subject must have at least one HLA-mismatch with the donor. HLA identical
             donor-recipient pairs are not eligible

          -  Subject understands either English or French

          -  If female and of child-bearing potential, subject has a negative pregnancy test and
             utilizes adequate contraceptive methods

        Exclusion Criteria:

          -  Presence of donor specific antibody

          -  Subject who is currently participating in a study with investigational drug, or who
             has received investigational drug within three months prior to randomization.
             Observational studies are acceptable

          -  Subject who has lost a previous graft for immunological reasons less than one year
             from transplant

          -  Subject is pregnant or breastfeeding

          -  Subject receives a kidney lacking pre-implantation biopsy

          -  Subject has significant disease (e.g. malignancy or uncontrolled infection) or
             disability (e.g. cognitive defect) which prevents understanding of, or adherence to
             the protocol

          -  Subject who in the opinion of the Investigator, require ACEi/ARB therapy
             post-transplant for any indication

          -  Subject who requires induction with Thymoglobulin, Campath, antithymocyte globulin
             (ATG), antilymphocyte globulin (ALG) or any biological induction agent other than
             basiliximab. Unplanned post-transplant use of these prohibited drugs for clinical
             indications post-transplant is allowed

          -  Subject has plans to become pregnant within 2 years post-transplant

          -  Subject who has a positive T-cell or B-cell crossmatch. Subjects with a weakly
             positive B-cell cross-match that tests negative following DTT reduction are acceptable

          -  Subject who has a requirement for maintenance immunosuppressant therapy with the
             exception of low dose steroid or mycophenolate mofetil (MMF). A subject who is on low
             dose tacrolimus maintenance therapy will be eligible provided the tacrolimus is
             withheld at least 1 week prior to transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Canada, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site CA133 Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA54 University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA141 Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA114 Capital District Health Authority- QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA150 St. Joseph's Healthcare</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA27 London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA165 St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5C 2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA238 Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA172 Hôpital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA144 McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA116 Centre Hospitalier Universitaire de Sherbrooke- Hôpital Fleuirmont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA142 St. Paul's Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7V 0Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site CA64 Centre Hospitalier Universitaire de Québec- L'Hôtel-dieu de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2009</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Advagraf</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Angiotensin-Converting Enzyme Inhibitors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

